Ocuflox has been approved for the treatment of corneal ulcers. The approval also supports the broader use of Ocuflox, which is already indicated for the treatment of bacterial conjunctivitis. Ocuflox is part of a class of anti-bacterial agents called fluoroquinolones that exhibit a broad spectrum of activity, low resistance, and favorable side-effects profile.